The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends that Genmab's Darzalex be authorized for use in combination with cancer treatment Velcade and drugs cyclophosphamide and dexamethasone for treating adults with systemic light-chain (AL) amyloidose.
This recommendation encompasses the injection-based version of Darzalex which is marketed as Darzalex SC in the EU and as Darzalex Faspro on other markets, according to a Genmab press release on Friday afternoon.
Aside from the treatment of AL amyloidosis, the CHMP also recommends that Darzalex SC is used in combination with celgene's imnovid and dexamenthason for treating patients with multiple myeloma who have received at least one prior therapy containing a proteasome inhibitor (PI) and lenalidomide, or who have demonstrated disease progression in spite of having received at least two prior therapies that included lenalidomide and a proteasome inhibitor (PI).
Formally, the application for EU marketing authorization was submitted by Genmab's official partner Janssen.
Analysts to home in on expenses in Genmab's Wednesday fiscal report
Janssen had better Darzalex sales than expected in Q1
Genmab CEO on possible settlement in dispute with Janssen: "I have no comment"
More from MedWatch
GN Hearing top exec stops after 17 years – replacement found within own ranks
The CEO of hearing company GN Hearing's US subsidiary Audigy is now retiring after 17 years in the hot seat. The company, which was acquired by GN Hearing in 2016, has found his replacement within own ranks.
Pharma industry is discretely working against a global tax agreement
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
Pfizer upgrades guidance for sales of covid-19 vaccine
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Astrazeneca shot shows no increased clot risk after two doses
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
Boston Scientific reports significant growth in endoscopy business – grows 54 percent
In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.
(Senior) Regulatory Science Specialist - IWA Consulting 
Clinical Development Coordinator - Vaccibody 
KLIFO is looking for a Senior CMC Expert/Senior CMC Project Manager for our Copenhagen office 
Employee for regulatory department 
Senior Validation Analyst, Zealand Pharma 
Regulatory Affairs Professional, CMC - ALK 
Sponsor Oversight Lead - Genmab 
Principal Scientist, In Vivo Pharmacology 
We are expanding in CleanZone and we are looking for a technical product specialist and technical project manager 
Business developer within Medical Diagnostics 
Associate Director, PV QA - Y-mAbs Therapeutics 
Manager/Associate Director Regulatory Affairs - Ascendis Pharma